2017
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression
Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, Masserdotti A, Zammataro L, Altwerger G, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clinical Cancer Research 2017, 23: 5836-5845. PMID: 28679774, PMCID: PMC5626613, DOI: 10.1158/1078-0432.ccr-16-2862.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAnimalsAntibody-Dependent Cell CytotoxicityCarcinosarcomaCell Line, TumorCell ProliferationDuocarmycinsFemaleGene Expression Regulation, NeoplasticHumansImmunoconjugatesIndolesMaytansineMiceOvarian NeoplasmsPyrrolidinonesReceptor, ErbB-2TrastuzumabUterine NeoplasmsXenograft Model Antitumor AssaysConceptsAntibody-dependent cellular cytotoxicityHER2/neu expressionHER2/neu 3T-DM1Antibody-drug conjugatesCS cell linesNeu expressionEffector cellsHigh HER2/neu expressionNeu 3HER2-targeting antibody-drug conjugateCell linesBystander killingPatient-derived xenograft modelsNovel HER2-targeting antibody-drug conjugateAggressive gynecologic malignancyHigh HER2 expressionEffective antibody-drug conjugatesHER2/neuClin Cancer ResGynecologic malignanciesOvarian carcinosarcomaHER2 expressionTrastuzumab emtansineSYD985SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.
Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Pettinella F, Masserdotti A, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi D, Azodi M, Schwartz P, Santin A. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression. Journal Of Clinical Oncology 2017, 35: e14009-e14009. DOI: 10.1200/jco.2017.35.15_suppl.e14009.Peer-Reviewed Original ResearchHER2/neu expressionHER2/neu 3Epithelial ovarian cancerAntibody-dependent cellular cytotoxicityAntibody-drug conjugatesT-DM1Neu expressionEOC cell linesNeu 3Low HER2/neu expressionHER2/neu 2HER2-targeting antibody-drug conjugateHER2 overexpression/amplificationNovel antibody-drug conjugateNovel HER2-targeting antibody-drug conjugateCell linesChemo-resistant diseaseEpithelial ovarian carcinomaOvarian cancer xenograftsLethal gynecological cancerOverexpression/amplificationAnti-tumor activityMonoclonal antibody trastuzumabEffector cellsEOC patients
2003
Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy
Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecologic Oncology 2003, 91: 231-240. PMID: 14529687, DOI: 10.1016/s0090-8258(03)00460-8.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityEarly-stage cervical cancerStage cervical cancerCervical cancer cell linesCancer cell linesCervical cancerPrimary cell linesNeu expressionPrimary cervical cancer cell linesCell linesHER-2/neu expressionSite of recurrenceInhibition of proliferationEffector cellsMetastatic lesionsIL-2Primary treatmentTumor biopsiesCellular cytotoxicityHumanized mAbOriginal tumorRecurrent sitesLow dosesFlow cytometryLow expression
2002
Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clinical Cancer Research 2002, 8: 1271-9. PMID: 12006548.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsBreast NeoplasmsCell DivisionCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousFemaleFlow CytometryHumansImmunohistochemistryInterleukin-2Killer Cells, NaturalMiddle AgedNeoplasm StagingOvarian NeoplasmsReceptor, ErbB-2RituximabTrastuzumabTumor Cells, CulturedUterine NeoplasmsConceptsUterine serous papillary carcinomaAntibody-dependent cellular cytotoxicityUSPC cell linesIntensity of expressionOvarian cancerPrimary USPC cell linesUterine serous papillary cancerCell linesFlow cytometryHigh-grade ovarian cancerOvarian cancer cell linesSerous papillary carcinomaCell proliferationComplement-dependent cytotoxicityComplement-mediated cytotoxicityAttractive therapeutic strategyHuman serum IgGCancer cell linesEndometrial cancerNatural killerAggressive variantEffector cellsSerum IgGPapillary cancerIL-2